- Home
- SAVA vs FORA Comparison
SAVA vs FORA Comparison
Compare SAVA & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- FORA
- Stock Information
- Founded
- SAVA 1998
- FORA 2014
- Country
- SAVA United States
- FORA United States
- Employees
- SAVA N/A
- FORA N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- SAVA Health Care
- FORA Technology
- Exchange
- SAVA Nasdaq
- FORA Nasdaq
- Market Cap
- SAVA 70.5M
- FORA 62.7M
- IPO Year
- SAVA N/A
- FORA N/A
- Fundamental
- Price
- SAVA $2.05
- FORA $1.95
- Analyst Decision
- SAVA Buy
- FORA Strong Buy
- Analyst Count
- SAVA 3
- FORA 1
- Target Price
- SAVA $54.50
- FORA $5.00
- AVG Volume (30 Days)
- SAVA 1.2M
- FORA 8.0K
- Earning Date
- SAVA 08-07-2025
- FORA 06-20-2025
- Dividend Yield
- SAVA N/A
- FORA N/A
- EPS Growth
- SAVA N/A
- FORA N/A
- EPS
- SAVA N/A
- FORA N/A
- Revenue
- SAVA N/A
- FORA $22,332,001.00
- Revenue This Year
- SAVA N/A
- FORA $13.31
- Revenue Next Year
- SAVA N/A
- FORA $43.65
- P/E Ratio
- SAVA N/A
- FORA N/A
- Revenue Growth
- SAVA N/A
- FORA 5.22
- 52 Week Low
- SAVA $1.15
- FORA $1.85
- 52 Week High
- SAVA $42.20
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- SAVA 51.70
- FORA 43.55
- Support Level
- SAVA $2.02
- FORA $1.95
- Resistance Level
- SAVA $2.25
- FORA $2.09
- Average True Range (ATR)
- SAVA 0.11
- FORA 0.13
- MACD
- SAVA -0.02
- FORA -0.01
- Stochastic Oscillator
- SAVA 29.03
- FORA 9.09
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.